Skip to main content
. 2018 Dec 25;9(101):37480–37496. doi: 10.18632/oncotarget.26459

Figure 4. Neuronal TFs FLI1, NEUROD1 and FOXG1 activate NKX2-2 expression.

Figure 4

(A) RQ-PCR analysis of FLI1 in HL cell lines (left) and primary hematopoietic cell/tissue samples (right). (B) RQ-PCR analysis of FLI1 and NKX2-2 in DEV cells after siRNA-mediated knockdown of FLI1 (left). RQ-PCR analysis of NKX2-2 and FLI1 in DEV cells after siRNA-mediated knockdown of NKX2-2 (middle). RQ-PCR analysis of IL17RB and NKX2-2 in DEV cells after siRNA-mediated knockdown of IL17RB (right). (C) RQ-PCR analysis of NEUROD1 in HL cell lines (left) and primary hematopoietic cell/tissue samples (right). (D) RQ-PCR analysis of NEUROD1 and NKX2-2 in DEV cells after siRNA-mediated knockdown of NEUROD1 (left). RQ-PCR analysis of NKX2-2 and NEUROD1 in DEV cells after siRNA-mediated knockdown of NKX2-2 (right). (E) RQ-PCR analysis of FOXG1 in HL cell lines (left) and primary hematopoietic cell/tissue samples (right). (F) RQ-PCR analysis of FOXG1 and NKX2-2 in DEV cells after siRNA-mediated knockdown of FOXG1 (left). RQ-PCR analysis of NKX2-2 and FOXG1 in DEV cells after siRNA-mediated knockdown of NKX2-2 (middle). RQ-PCR analysis of IL17RB and FOXG1 in DEV cells after siRNA-mediated knockdown of IL17RB (right).